OLIX
LIVE

Serial Number

79334635

Owner

OliX Pharmaceuticals, Inc.

Attorney

Joesph A. R. Gerber

Filing Date

Dec 24, 2021

Add to watchlist:

No watchlists yet
View on USPTO

OLIX Trademark

Serial Number: 79334635 • Registration: 7435162

OLIX is a trademark filed by OliX Pharmaceuticals, Inc. on December 24, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

OliX Pharmaceuticals, Inc.

1014, 17, Daehak 4-ro,

Entity Type: 03

Trademark Details

Filing Date

December 24, 2021

Registration Date

July 9, 2024

Published for Opposition

April 23, 2024

Goods & Services

Dietary supplements; nucleic acid sequences for medical purposes; cultures of microorganisms for medical use; biotechnological preparations for medical use, namely, cells, recombinant DNA sequences, synthetic RNA sequences, and oligonucleotides for use in treating and repairing damaged human tissue through tissue nanotransfection (TNT); reagent paper for medical purposes; drugs for medical purposes, namely, cardiovascular pharmaceuticals, anti-diabetic pharmaceuticals, metabolic pharmaceuticals, antibacterial pharmaceuticals, macular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals), hair loss treatment pharmaceuticals, hepatitis treatment pharmaceuticals, respiratory disease treatment pharmaceuticals, neurological disease treatment pharmaceuticals, hepatological disease treatment pharmaceuticals; synthetic peptides for the treatment of metabolic, ophthalmic, cardiovascular, pulmonary, hepatological, respiratory, neurological diseases and disorders; cardiovascular pharmaceuticals, anti-diabetic pharmaceuticals, antibacterial pharmaceuticals, macular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals), hair loss treatment pharmaceuticals, hepatitis treatment pharmaceuticals, respiratory disease treatment pharmaceuticals, neurological disease treatment pharmaceuticals, hepatological disease treatment pharmaceuticals; materials for dental fillings; colostral antibodies for medical purposes, monoclonal antibodies for medical purposes, hybrid antibodies for medical purposes; all the foregoing for human use and excluding goods related to the care and feeding of animals and plants

Product research and development in the field of biotech technology; scientific research in the field of biotechnology, medical research in the field of biotechnology; scientific research and scientific investigations for medical purposes in the field of biomedicine; scientific research consultation and providing scientific research information both of the foregoing in the field of biomedicine; bacteriological research; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; pharmaceutical research services; scientific research in the field of genetics; medical research laboratory services; Scientific research and scientific investigations for medical purposes, both of the foregoing in the fields of medicine, health and pharmacology; medical research; All the above-mentioned services excluding services related to the care and feeding of animals and plants

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 4, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 13, 2024 FICS
FINAL DISPOSITION PROCESSED
Dec 13, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 9, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 9, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 9, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Apr 29, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 23, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 10, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 10, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 12, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 6, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 6, 2024 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 13, 2024 OPNX
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Jan 8, 2024 GNS1
CONTINUATION OF FINAL REFUSAL E-MAILED
Jan 8, 2024 GNCF
ACTION CONTINUING A FINAL - COMPLETED
Jan 8, 2024 CNCF
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 27, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 27, 2023 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 22, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 21, 2023 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 21, 2023 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 24, 2023 GNFN
FINAL REFUSAL E-MAILED
May 24, 2023 GNFR
FINAL REFUSAL WRITTEN
May 24, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 3, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 2, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 2, 2023 TROA
ATTORNEY REVIEW COMPLETED
Feb 1, 2023 ATRV
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Jan 12, 2023 LIME
REFUSAL PROCESSED BY IB
Jan 4, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 12, 2022 RFCS
REFUSAL PROCESSED BY MPU
Dec 12, 2022 RFRR
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Oct 28, 2022 CREV
LIMITATION OF GOODS RECEIVED FROM IB
Oct 1, 2022 LIMG
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 29, 2022 RFCR
NON-FINAL ACTION WRITTEN
Sep 28, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 28, 2022 DOCK
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 23, 2022 CRCV
APPLICATION FILING RECEIPT MAILED
Mar 15, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 10, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 3, 2022 REPR